Slide 1: Ipsen Q3 2019 Sales
Marin Living with fibrodysplasia ossificans progressiva Hamilton, Canada Ipsen Q3 2019 Sales October 24, 2019
Slide 2: Disclaimer & Safe Harbor
Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management’s current views and assumptions. Such statements in
Slide 3: Delivering on growth strategy
Delivering on growth strategy Focused execution Strong YTD 2019 Confirmation of 2019 Rapidly advancing to drive three-fold Group sales growth of financial objectives of pipeline driving value growth strategy: +14.3%1 driven by sales growth greater creation including • Top-line continued momentum tha
Slide 4: YTD 2019 sales growth driven by Specialty Care
YTD 2019 sales growth driven by Specialty Care Net sales of key products YTD in 2019 in million euros – % excluding foreign exchange impact Group sales Specialty Care sales €1,874m Somatuline® 743 +16% +14.3%1 Decapeptyl® 297 +9% Cabometyx® 176 +75% Specialty Care Onivyde® 101 +25% €1,674m Dysport®
Slide 5: YTD 2019 performance highlights for key products
YTD 2019 performance highlights for key products Ronny Living with neuroendocrine tumors Ringwood, UK Oncology Neuroscience Somatuline • Strong performance in the U.S. in both • Acceleration of growth in Q3: U.S. growth of 20% and double-digit growth therapeutics and aesthetics in EU5 driven by volu
Slide 6: Delivering growth across all geographic regions
Delivering growth across all geographic regions Net sales YTD in 2019 in million euros, % excluding foreign exchange impact EU5 +16% North America +19% Other European countries +9% Rest of World +11% 0 200 400 600 800 EU5: European Union Five (France, Germany, Italy, Spain, United Kingdom) 6
Slide 7: No impact in Q3 on Somatuline from EU octreotide generic
No impact in Q3 on Somatuline from EU octreotide generic Double-digit growth in EU5 in Q3 2019 EU5 represents less than 30% of Somatuline sales Germany: First and only EU5 country to launch octreotide generic to date • Somatuline continues volume growth • No impact on list price Expectations for sta
Slide 8: Palovarotene program progressing
Palovarotene program progressing Regulatory timelines Launch preparations underway Regulatory submission for palovarotene for episodic FOP now • Active patient identification efforts with ~1,000 patients expected in Q1 2020 in U.S., followed by EU and worldwide already identified in reimbursable ter
Slide 9: Advancing R&D pipeline driving value creation
Advancing R&D pipeline driving value creation Onivyde Phase 2 trial in 1L PDAC – Presented at ESMO-GI in July • Positive interim data - DCR of 72% at 16 weeks or 81% best overall response • Phase 3 registrational trial vs. gemcitabine/Abraxane to begin imminently Onivyde Phase 2 trial in 2L SCLC – P
Slide 10: Strengthening leadership in FOP with in-licensing of BLU-782 from Blueprint
Strengthening leadership in FOP with in-licensing of BLU-782 from Blueprint Exclusive global license to develop and commercialize BLU-782, a highly selective and potent orally-administered ALK2 inhibitor for the treatment of FOP • Portfolio strategy: Complementary drug candidate to bolster Ipsen’s R
Slide 11: 2019 Objectives
2019 Objectives Growth Pipeline Culture • Maximize growth and market share • Increase value of the pipeline by • Drive further transformation and worldwide for differentiated best-in- accelerating key internal R&D ambition through leadership and class Specialty Care products programs people • Contin
Slide 12: Thank You
Marin Living with fibrodysplasia ossificans progressiva Hamilton, Canada Thank You